scispace - formally typeset
T

Tanya N. Turan

Researcher at Medical University of South Carolina

Publications -  126
Citations -  51257

Tanya N. Turan is an academic researcher from Medical University of South Carolina. The author has contributed to research in topics: Stroke & Angioplasty. The author has an hindex of 40, co-authored 113 publications receiving 45796 citations. Previous affiliations of Tanya N. Turan include Stony Brook University & Johns Hopkins University.

Papers
More filters
Journal ArticleDOI

Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

TL;DR: Management of RH includes maximization of lifestyle interventions, use of long-acting thiazide-like diuretics, addition of a mineralocorticoid receptor antagonist (spironolactone or eplerenone), and, if BP remains elevated, stepwise addition of antihypertensive drugs with complementary mechanisms of action to lower BP.
Journal ArticleDOI

Current Science on Consumer Use of Mobile Health for Cardiovascular Disease Prevention: A Scientific Statement from the American Heart Association

TL;DR: It was revealed that people who met ≥6 of the cardiovascular health metrics had a significantly better risk profile compared with individuals who had achieved only 1 metric or none, and National Health and Nutrition Examination Survey (NHANES) data revealed.
Journal ArticleDOI

Atherosclerotic intracranial arterial stenosis: risk factors, diagnosis, and treatment

TL;DR: Non-invasive vascular imaging methods that could be used to identify high-risk patients include fractional flow on magnetic resonance angiography (MRA), quantitative MRA, and high-resolution MRI of the atherosclerotic plaque.
Journal ArticleDOI

Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation A Science Advisory for Healthcare Professionals From the American Heart Association/American Stroke Association

TL;DR: Recent trials testing the safety and efficacy of a thrombin inhibitor (dabigatran) and 2 factor Xa inhibitors (rivaroxaban and apixaban) in preventing stroke in patients with AF are reviewed, and management recommendations are revised.